Medvedev V E, Tereshchenko O N, Israelian A Iu, Chobanu I K, Kost N V, Sokolov O Iu, Miasoedov N F
Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22.
Objective. To study the efficacy and tolerability of the new anxyolytic peptide selank in comparison with phenazepam. Material and methods. A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2-9, F41.1-9, F45.0-1 by ICD-10) were examined. Results Pronounced anxiolytic and mild nootropic effects of selank were demonstrated. The anxiolytic effect lasted for a week after last receiving the peptide. Selank had a positive impact on the quality of life of the patients. Conclusion. The data obtained in the study extend therapeutic possibilities in the treatment of anxiety disorders.
目的。比较新型抗焦虑肽selank与苯那西泮的疗效和耐受性。材料与方法。对60例患有恐怖-焦虑和躯体形式障碍（根据国际疾病分类第十版为F40.2 - 9、F41.1 - 9、F45.0 - 1）的患者进行了selank和苯那西泮抗焦虑作用及耐受性的比较研究。结果显示selank具有显著的抗焦虑作用和轻度的促智作用。最后一次给予该肽后，抗焦虑作用持续一周。Selank对患者的生活质量有积极影响。结论。该研究获得的数据拓展了焦虑症治疗的可能性。
